IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company. It discovers and develops potent and specific inhibitors of the complement activation factor known as C5a.

$3.41
As of 05/10/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  
IPO date:  11/08/2017
Outstanding shares:  43,228,415
Average volume:  201,015
Market cap:   $156,486,862
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    N44821101
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.24
PS ratio:   0.00
Return on equity:   -43.64%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy